Connect with us
Eli Lilly will invest $3 billion to expand its Kenosha, Wisconsin, facility, acquired for $100 million in April. The site will manufacture injectable diabetes and obesity...
Eli Lilly posted a $970.3 million profit in Q3, boosted by 20.4% growth in sales despite a $1 billion loss in market value. Oversupply issues arose...
Eli Lilly is expanding its presence with the opening of a 346,000-square-foot facility in Boston, which will house 500 scientists and the first East Coast location...
Eli Lilly's first-half 2023 revenues surged 31% to $20 billion, driven by Mounjaro's $4.9 billion in sales, dominating the company’s earnings. Trulicity, in contrast, saw a...
Augustine Therapeutics raised 17 million euros in the first closing of a Series A round led by Asabys Partners. Eli Lilly & Company and the CMT...
Eli Lilly is investing $5.3 billion in a new Indiana plant to increase production of diabetes and weight loss drugs, raising total facility investment to $9...
Eli Lilly's first-quarter results exceeded expectations, with a $8.77 billion turnover, a 26% year-on-year growth, and $2.24 billion net income, 67% higher than in 2023. Strong...
Eli Lilly's U.S. revenues grew by 39% to 6,188.1 million euros, with international revenues up 10% to 2.7 billion euros. R&D costs rose by 29.5%, while...
The pharmaceutical company Eli Lilly has added that it will invest $100 million with the aim of boosting its footprint in the German biotechnology ecosystem. The...
Eli Lilly unites healthcare and research to create medicines that improve the lives of people around the world. Harnessing the power of biotechnology, chemistry, and genetics, its scientists are...